Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

10.61 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherap

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Host EBV and MS Day
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares rose 172.1% to $0.92 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 157.8... 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Fujifilm To Buy Cell Therapy Plant From Atara For $100M
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, will acquire a cell therapy plant from Atara Biotherapeutics Inc (NASDAQ: ATRA)  
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
80 Biggest Movers From Yesterday
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63... 
Via Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the... 
Via Benzinga
Preview: Atara Biotherapeutics's Earnings
Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
Via FinancialNewsMedia
Exposures COVID-19
Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial
Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patient in Phase 1 study of Atara... 
Via Benzinga
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
From Atara Biotherapeutics, Inc.
Via Business Wire
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
From Be The Match BioTherapies
Via Business Wire
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients
Atara Biotherapeutics Inc (NASDAQ: ATRA) posted efficacy and safety results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement... 
Via Benzinga
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.